Chronic Diseases and Translational Medicine最新文献

{"title":"Guide for Authors","authors":"","doi":"10.1002/cdt3.70021","DOIUrl":"https://doi.org/10.1002/cdt3.70021","url":null,"abstract":"","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"241-248"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next-Generation PD-1 Immunotherapy","authors":"Thy T. Nguyen,&nbsp;Bohan Zhang,&nbsp;Luke Zhong,&nbsp;Xiuyi Liang,&nbsp;Letao Bo","doi":"10.1002/cdt3.70017","DOIUrl":"https://doi.org/10.1002/cdt3.70017","url":null,"abstract":"<p>Tislelizumab is a next-generation PD-1 monoclonal antibody developed to overcome the limitations of earlier immune checkpoint inhibitors. By eliminating Fcγ receptor binding, it avoids macrophage-mediated T-cell clearance and enhances the antitumor immune response. Unlike conventional PD-1 inhibitors, tislelizumab binds to PD-1 in a way that more closely mimics the natural PD-L1 interaction, potentially improving efficacy and reducing immune-related toxicity. This review highlights its structural advantages, clinical efficacy across multiple cancers, and recent global regulatory approvals. We also discuss key pharmacokinetic features and current challenges, including the need for predictive biomarkers, immune-related adverse events, and combination therapy strategies. Together, these insights may guide the more effective and safer use of tislelizumab in cancer immunotherapy.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"173-185"},"PeriodicalIF":0.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Chronic Body Pain and Depression Among Middle-Aged and Elderly People in China: A Longitudinal Population-Based Study From CHARLS","authors":"Jiaying Wang,&nbsp;Kai Wang,&nbsp;Qingxia Gao,&nbsp;Wenchang Xu,&nbsp;Gongchang Yu,&nbsp;Bin Shi","doi":"10.1002/cdt3.70016","DOIUrl":"https://doi.org/10.1002/cdt3.70016","url":null,"abstract":"<p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"232-236"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HDL-C/LDL-C Ratio and All-Cause Mortality in Populations at High CVD Risk: A Prospective Observational Cohort Study","authors":"Biting Lin,&nbsp;Yunzhi Ling,&nbsp;Gengyu Zhou,&nbsp;Ziqing Ruan,&nbsp;Fan Chen,&nbsp;Simiao Chen,&nbsp;Tingting Weng,&nbsp;Yuanfan Zhu,&nbsp;Jingyi Lin,&nbsp;Ling Yu,&nbsp;Kaiyang Lin","doi":"10.1002/cdt3.70013","DOIUrl":"https://doi.org/10.1002/cdt3.70013","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The ratio of high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C) predicts cardiovascular disease (CVD) endpoints, yet its prognostic validity in high-risk populations and for type 2 diabetes mellitus (T2DM)-related adverse events remains unestablished.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included 32,609 people aged 35–75 years in Fujian Province, China, who were at high risk for CVD. The primary endpoint was all-cause mortality during follow-up. Cox proportional hazard models and restricted cubic spline (RCS) analysis were used to evaluate the correlation between the HDL-C/LDL-C ratio and the endpoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>On the basis of the restricted RCS curve, the participants were classified as having a low (&lt; 0.3), middle (0.3–0.5), or high (&gt; 0.5) HDL-C/LDL-C ratio. Multivariate Cox regression analyses revealed that the risk of all-cause mortality (HR = 1.48, 95% CI 1.14–1.93, <i>p</i> &lt; 0.01 for low; HR = 1.30, 95% CI 1.06–1.58, <i>p</i> &lt; 0.05 for high) was increased in the low and high groups. Participants without T2DM who were at high risk for CVD had similar prognoses (HR = 1.65, 95% CI 1.19–2.28, <i>p</i> &lt; 0.01 for low; HR = 1.35, 95% CI 1.05–1.74, <i>p</i> &lt; 0.01 for high). However, this association was not found in participants with T2DM who were at high risk for CVD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HDL-C/LDL-C can be used to predict the prognosis of individuals at high risk for CVD, and maintaining HDL-C/LDL-C ratios between 0.3 and 0.5 may be the most helpful range for this population. Furthermore, maintaining this ratio range holds clinical significance for cohorts without T2DM, although further exploration is needed in this T2DM cohort.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"213-223"},"PeriodicalIF":0.0,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Cohort Study of Metabolomic Markers Associated With Type 2 Diabetes Risk in Korean Adults","authors":"Md. Kamruzzaman,&nbsp;Catherine Apio,&nbsp;Md. Mozaffar Hosain,&nbsp;Min Kyong Moon,&nbsp;Geum-Sook Hwang,&nbsp;Eunyong Ahn,&nbsp;Taesung Park","doi":"10.1002/cdt3.70014","DOIUrl":"https://doi.org/10.1002/cdt3.70014","url":null,"abstract":"<p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"224-231"},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Vitamin D in Diabetes Ketosis and Ketoacidosis","authors":"Cui Zhang,&nbsp;Jia Liu,&nbsp;Sumita Cholekho,&nbsp;Qin Pei,&nbsp;Huiwen Tan","doi":"10.1002/cdt3.70015","DOIUrl":"https://doi.org/10.1002/cdt3.70015","url":null,"abstract":"&lt;p&gt;Diabetes mellitus (DM) is a common endocrine and metabolic disorder, and diabetes ketosis (DK) is a significant acute complication. Individuals with type 1 DM (T1DM) are inherently at risk for diabetic ketoacidosis (DKA). Individuals with T2DM may develop DK under certain conditions, including infection, interruption of insulin therapy, stress, or excessive alcohol consumption. Recent studies have indicated that vitamin D supplementation reduces the risk of progression from prediabetes to T2DM and that it may also be involved in the prevention of diabetes complications. Yet most previous research has been observational correlations rather than interventional trials.&lt;/p&gt;&lt;p&gt;The relationship between metabolic, cardiovascular, and autoimmune diseases and 25[OH]D levels has been explored in several studies. A retrospective study conducted in Morocco examined 200 pediatric patients (aged 1–18 years) with T1DM during 2019 and 2023. The results suggested a possible link between vitamin D and the risk of developing DKA. Specifically, patients with DKA had lower levels of 25[OH]D compared to those without DKA at the onset of T1DM. Furthermore, more severe acidosis was associated with lower concentrations of 25[OH]D [&lt;span&gt;1&lt;/span&gt;]. Vitamin D levels also appear to be associated with ketosis episodes in individuals with ketosis-prone type 2 diabetes (KPT2D). In these patients, serum 25[OH]D has been found to be an independent factor that helps prevent bouts of ketosis episodes [&lt;span&gt;2&lt;/span&gt;]. These findings suggest that vitamin D deficiency may predispose patients to a greater risk of metabolic decompensation in both T1DM and T2DM settings.&lt;/p&gt;&lt;p&gt;Vitamin D supplementation combined with lifestyle changes has been recommended to those with a high risk of DM as a means of diabetes risk reduction and improvement of impaired glucose regulation (IGR). However, its effects seem to be more marked in nonobese individuals, and evidence that this also applies to obese populations remains limited [&lt;span&gt;3, 4&lt;/span&gt;]. Notably, pediatric studies demonstrate compelling associations between vitamin D status and diabetes management. A 3-month intervention with vitamin D in pediatrics diagnosed with T1DM and vitamin D deficiency reduced HbA1c levels, underscoring its potential role in glycemic optimization [&lt;span&gt;5&lt;/span&gt;]. Another prospective study, which included 90 patients with uncontrollable T1DM and vitamin D deficiency at the Specialized Center for Endocrinology and Diabetes in Baghdad, Iraq, showed a high frequency of vitamin D deficiency, closely related to poor glycemic control [&lt;span&gt;6&lt;/span&gt;]. Studies in children have shown that pediatrics with DKA tend to have lower median 25[OH]D levels than those without DKA. This supports the recommendation to include vitamin D supplements in managing T1DM and acute diabetes crises [&lt;span&gt;7&lt;/span&gt;]. Preclinical validation emerges from diabetic Wistar rat models, where vitamin D supplementation attenuated fasting hypergly","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"237-238"},"PeriodicalIF":0.0,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guide for Authors","authors":"","doi":"10.1002/cdt3.70012","DOIUrl":"https://doi.org/10.1002/cdt3.70012","url":null,"abstract":"","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"162-169"},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Shingles Vaccination Reduces the Risk of Parkinson's Disease”","authors":"","doi":"10.1002/cdt3.70009","DOIUrl":"https://doi.org/10.1002/cdt3.70009","url":null,"abstract":"<p>S. Lehrer and P. H. Rheinstein, “Shingles Vaccination Reduces the Risk of Parkinson's Disease,” <i>Chronic Diseases and Translational Medicine</i> 9 (2023): 54−57, https://doi.org/10.1002/cdt3.50.</p><p>The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article.</p><p><b>Conflicts of Interest</b></p><p>Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma, Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic Changes Related to Hypertension in Asian Adults: A Systematic Review","authors":"Lilik Sukesi,&nbsp;Yunia Sribudiani,&nbsp;Steven Yulius Usman,&nbsp;Eric Ricardo Yonatan,&nbsp;Ahmedz Widiasta,&nbsp;Noormarina Indraswari,&nbsp;Ria Bandiara,&nbsp;Nanny N. M. Soetedjo","doi":"10.1002/cdt3.70008","DOIUrl":"https://doi.org/10.1002/cdt3.70008","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Elevated high blood pressure is controlled by complicated, little-understood genetic and epigenetic pathways that are influenced by both heritable and environmental variables. Many adult systolic and diastolic blood pressure-related genomic loci have been identified through previous genome-wide association studies (GWAS); meanwhile, studies specifically on Asian adult populations have not been done. This study aims to comprehensively assess and summarize any gene changes that have been studied and see whether there is a possible influence between epigenetic changes and hypertension in Asian adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This evidence-based analysis is based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement and has been registered in PROSPERO under registration number [CRD42024622261]. The data were processed qualitatively to assess the risk of bias using the Newcastle–Ottawa Scale (NOS) and Agency for Health Research and Quality (AHRQ) standards as the threshold. Our study in particular shows that epigenetic modifications may play a role in hypertension, particularly in Asian individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 28 studies were selected for qualitative evaluation. In the adult Asian population, 26 publications (92.8%) reported a relationship between blood pressure and epigenetics. Every study describes a distinct gene or location associated with hypo- or hypermethylation. Elevated systolic and diastolic blood pressure was linked to variations of several single-nucleotide polymorphisms (SNPs), cytosine phosphate guanines (CPGs), and other monogenic genes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Alterations in epigenetic modifications in potential genes or loci are linked to systolic and diastolic blood pressure of Asian adult populations.</p>\u0000 \u0000 <p><b>PROSPERO Protocol Registration:</b> CRD42024622261.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"197-204"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol for an Integrative Meta-Analysis of the Application of Machine Learning Algorithms in the Prediction of Chronic Disease Risks and Outcomes","authors":"Ebenezer Afrifa-Yamoah,&nbsp;Emmanuel Peprah-Yamoah,&nbsp;Enoch Odame Anto,&nbsp;Victor Opoku-Yamoah,&nbsp;Eric Adua","doi":"10.1002/cdt3.70007","DOIUrl":"https://doi.org/10.1002/cdt3.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Precise risk prediction of chronic diseases is essential for effective preventive care and management. Machine learning (ML) is a promising avenue to enhance chronic disease risk prediction; however, a comprehensive assessment of ML performance across various chronic diseases, populations, and health settings is needed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This meta-analysis aims to synthesize evidence on the performance of ML techniques for predicting the risks and outcomes of chronic diseases. A literature search was conducted through PubMed, Web of Science, Scopus, Science Direct, Medline, and Embase. Studies applying ML techniques to predict chronic disease risks or outcomes and reporting performance metrics were included. Two reviewers independently screened studies, extracted data, and assessed the risk of bias. Random-effects meta-analysis, subgroup analyses, and meta-regression were performed to estimate pooled performance and explore heterogeneity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This meta-analysis provides a comprehensive evaluation of the performance of ML techniques in predicting the risks and consequences of chronic diseases. We reported the pooled estimates of performance metrics, such as the area under the receiver operating characteristic curve (AUC-ROC), sensitivity, specificity, and F1 score, for each chronic disease. Subgroup analyses and meta-regression identified factors that influence the performance of ML models, such as the ML algorithm, sample size, and data type. This meta-analysis synthesized evidence on ML techniques for chronic disease risk prediction, guiding the development of robust and generalizable ML-based tools. By identifying best practices and addressing challenges, this work advances predictive analytics in healthcare, facilitates translation into clinical practice, and ultimately improve patient outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> PROSPERO Protocol Registration</h3>\u0000 \u0000 <p>CRD42024566680.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"205-212"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}